IPSS

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Patient, RNA, Medical Subject Headings, Liver, Marketing, INN, Risk, Classification, Bone marrow, ATC, IPSS, International, WHO, B cell, Myeloid tissue, Azacitidine, Myelodysplastic syndrome, CMML, DNA, Nausea, Blood, Language, MDS, Cancer, Abdomen, Death, Myelocyte, European Medicines Agency, Syndrome, Monocyte, Thigh, Growth, Select, HSCT, Anatomy, AML, Pancreatic serous cystadenoma, Acute leukemia, IIA, Skin, Cytidine, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Marketing, INN, Risk, Leukopenia, Woman, Nausea, DNA, Cancer, Death, Anatomy, Pancreatic serous cystadenoma, IIA, CHMP, Skin, Bone marrow, ATC, IPSS, Myeloid tissue, European, Ageing, MDS, Abdomen, Kidney, Neutrophil, Blood, Syndrome, Thigh, Patient, RNA, Medical Subject Headings, European Commission, WHO, B cell, International, Neutropenia, Language, CMML, Myelodysplastic syndrome, Thrombocytopenia, Monocyte, Select, HSCT, Medicine, Vomiting, Cytidine, Survival, Classification, Stomach, Myelocyte, Growth, Committee, AML, Acute leukemia, Medical device

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Indigenous Partnerships Success Showcase celebrates five years of bringing together Indigenous leaders, government and business innovators, returning on June 5 & 6, 2024

Retrieved on: 
Monday, December 11, 2023
First Nations, Policy, TELUS, Goldman Sachs, Natural Resources, Government, Telecommunications, Digital, IPSS, Musqueam Indian Band, Vancouver Convention Centre, Entrepreneurship

VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Indigenous Partnerships Success Showcase (IPSS), a premier platform for celebrating Indigenous success, fostering partnerships and promoting sustainable development, returns June 5 and 6, 2024.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Indigenous Partnerships Success Showcase (IPSS), a premier platform for celebrating Indigenous success, fostering partnerships and promoting sustainable development, returns June 5 and 6, 2024.
  • The theme for the fifth annual Vancouver-based conference is “Reconciliation in Action.” GCT Global Container Terminals is returning as the event’s patron sponsor, alongside digital sponsor TELUS.
  • Registration for this signature event is now available at an early bird rate of 15% off the regular ticket price (offer ends February 1, 2024).
  • “I encourage business and government leaders to join me at IPSS 2024 to celebrate that success and discover new ways to take action on reconciliation."

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Retrieved on: 
Monday, December 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Yale Cancer Center, Associate, International Prognostic Scoring System, Quality, IPSS, VAF, ASH, Acute myeloid leukemia, Cytopenia, Risk, Pros, Corporation, Yale school, Fatigue, Patient, Thrombocytopenia, Research, Periodic breathing, Imetelstat, Quality of life, Internal medicine, MDS, Neutropenia, MBBS, Yale School of Medicine, Bleeding, Survival, Pain, AML, Geron Corporation, Society, Iron overload, Mutation, RBC, Pharmaceutical industry, Dietary supplement, Lancet, Geron, SF3B1, Blood, Medicine, Hematology

The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.

Key Points: 
  • The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.
  • Overall, durable 24-week and 1-year RBC-TI responses were observed with imetelstat in all lower- and higher-risk subgroups.
  • This analysis suggests clinical benefit of imetelstat across different molecularly defined subgroups and independent of the underlying molecular mutation pattern.
  • This analysis indicates that achievement of RBC-TI was associated with improved survival, suggesting that transfusion dependence is a modifiable predictor of clinical outcomes in lower risk MDS.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, International Prognostic Scoring System, IPSS, Survival, FDA, RUNX1, H. Lee Moffitt Cancer Center & Research Institute, VAF, Food, TP53, Thrombocytopenia, Literature, EZH2, MDS, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Imetelstat, Society, ASXL1, SF3B1, Transfusion-dependent anemia, Geron Corporation, Risk, Abstract, TI, EMA, Corporation, LR, Anemia, ETV6, Patient, Neutropenia, Mutation, Pharmaceutical industry, Communications satellite, ASH

Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.

Key Points: 
  • Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
  • “Additionally, our abstract showcasing a real-world data population level analysis of over 5,000 lower risk MDS patients adds to the significant literature suggesting a correlation between TI and improvement in survival.
  • This analysis suggests imetelstat has clinical activity in lower risk MDS patients independent of risk categories.
  • Achievement of durable TI was associated with improved survival, supporting the clinical benefit of achieving transfusion independence in lower risk MDS.

OJJAARA™ (momelotinib) Now Available from Onco360 For the Treatment of Intermediate or High-Risk Myelofibrosis (MF), Including Primary MF or Secondary MF [Post-Polycythemia Vera (PV) and Post- Essential Thrombocythemia (ET)], in Adults with Anemia

Retrieved on: 
Monday, September 25, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, GSK plc, System, Prevalence, Primary myelofibrosis, International Prognostic Scoring System, Survival, National Comprehensive Cancer Network, Pharmacy, MF, PV, NCCN, Pancreatic serous cystadenoma, Incidence, ET, Specialty pharmacy, Patient, Anemia, Diagnosis, MPN, IPSS, Pharmaceutical industry

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib).
  • OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
  • “Onco360 is grateful for the opportunity to partner with the team at GlaxoSmithKline and become a specialty pharmacy provider for OJJAARA,” said Benito Fernandez, Chief Commercial Officer.
  • The median age at time of original primary MF diagnosis is 67 years old.

Seoul St. Mary's Hospital Found Red Ginseng Oil is Excellent for Improving Prostatic Hyperplasia

Retrieved on: 
Thursday, September 14, 2023
Korea Ginseng Corporation, Retention rate, Urine, BPH, KGC, International Prostate Symptom Score, Nocturia, Research, Multimedia, JUNG, Malignancy, Capsule, Professor, Patient, Hospital, Department of Urology, University of Virginia, Ageing, Benign prostatic hyperplasia, Dietary supplement, IPSS

SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.

Key Points: 
  • SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.
  • Led by Professor Kim Sae Woong from the Department of Urology at Seoul St. Mary's Hospital, in collaboration with the Korea Ginseng Corporation (KGC), this research's results indicate that the intake of red ginseng oil extracted from JUNG KWAN JANG's RXGIN can safely and effectively improve prostatic hyperplasia.
  • It turns out that, compared to a mere 3.7% improvement in the control group, the red ginseng oil group experienced a significant 50.5% improvement in the red ginseng oil group in IPSS.
  • Professor Kim explained, "We found that red ginseng oil not only significantly improves the symptoms of BPH but also enhances dysfunction, which are the side effects of existing BPH(Benign prostatic hyperplasia) treatments."

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Indigenous Partnerships Success Showcase: Accelerating Reconciliation through better business relationships brings together government, business innovators and Indigenous leaders

Retrieved on: 
Thursday, June 1, 2023
Musqueam Indian Band, IPSS, Speech, Pacific Economic Cooperation Council, Vancouver Convention Centre, RoseAnne Archibald, Haisla Nation, International development

The event will take place at the Vancouver Convention Centre (West) on the traditional territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and Sel̓íl̓witulh (Tsleil-Waututh) Nations.

Key Points: 
  • The event will take place at the Vancouver Convention Centre (West) on the traditional territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and Sel̓íl̓witulh (Tsleil-Waututh) Nations.
  • Assembly of First Nations National Chief RoseAnne Archibald will feature prominently at the conference, delivering a keynote speech outlining her vision for economic reconciliation.
  • The conference aims to emphasize the critical role of cultural recognition and respect in establishing successful partnerships in business and beyond.
  • Participants will have the opportunity to connect, learn and be inspired by the remarkable achievements of Indigenous communities in Canada.

National Chief RoseAnne Archibald to headline 4th annual Indigenous Partnerships Success Showcase in Vancouver June 1 and 2

Retrieved on: 
Monday, May 29, 2023
Haisla Nation, APTN, Vancouver Community College, Tourism, RoseAnne Archibald, First Nations Bank of Canada, Telecommunications, Culture, Coalition, LNG Canada, International development, Sto꞉lo Nation Chiefs Council, Movement, Natural Resources, Salmon, LNG, Treaty, National Chief, Outline, Native Friendship Centre, Hearing, Mining, First Nations, Treaty 8, Williams Lake, Asia-Pacific Economic Cooperation, National Association, Williams Lake First Nation, TELUS, IPSS, Management, Whaling

VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Assembly of First Nations National Chief RoseAnne Archibald will feature prominently at the annual Indigenous Partnerships Success Showcase (IPSS) conference that seeks to get all Canadians working together to accelerate the pace of reconciliation through better business relationships.

Key Points: 
  • VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Assembly of First Nations National Chief RoseAnne Archibald will feature prominently at the annual Indigenous Partnerships Success Showcase (IPSS) conference that seeks to get all Canadians working together to accelerate the pace of reconciliation through better business relationships.
  • "National Chief Archibald's unwavering dedication to enhancing the well-being of Indigenous peoples spans decades.
  • Open to all, IPSS will leave delegates from diverse sectors better equipped to drive all types of enterprises to greater success in partnerships involving business, communities and governments.
  • On June 1, National Chief Archibald will outline her vision for economic reconciliation, followed by a discussion with award-winning journalist Tina House from APTN.